Air Liquide to Supply Oxygen to LG Chem for their Electric Vehicle Battery Plant in the United States
PARIS, October 15, 2024--(BUSINESS WIRE)--Regulatory News:
Air Liquide (Paris:AI) will invest around 150 million US dollars to expand its production capacity and pipeline network in Tennessee, U.S., in the context of a new long-term contract with LG Chem. Supplying oxygen to LG Chem's future cathode active material plant, the Group will be supporting the growth of the battery ecosystem in the United States. This investment will increase the Group's footprint in a key region and support the development of its Industrial Merchant market.
Triggered by LG Chem's new need for oxygen at their future cathode active material manufacturing plant for lithium-ion electric vehicle batteries, Air Liquide is investing 150 million US dollars to build, own and operate a second ASU, liquefier, storage and a pipeline at its Airgas production facility located in Clarksville, Tennessee.
This investment reflects how the Air Liquide group is solidly positioned to accompany its customers in the new Energy Transition markets, including the structurally growing battery manufacturing sector. The number of electric cars globally is expected to more than triple by 20301.
As part of this investment, the expansion of the Airgas facility, first inaugurated in 2013, is expected to be commissioned in 2027. It will produce additional oxygen, nitrogen and argon enabling the Group to seize growth opportunities, and ensure a better density coverage of the region with a reliable supply to industrial, healthcare, pharmaceutical, food production, water treatment and other customers throughout Kentucky and Tennessee. The Group will leverage electricity from renewable sources to produce and make low-carbon products available to customers.
Matthieu Giard, Group Vice President, Americas, said: "Serving a key industry in the energy transition, this investment is in line with the Group's ADVANCE strategic plan and our commitment to supporting our customers with concrete solutions. This is further recognition of our expertise in the United States, where the energy transition is gaining momentum and where we benefit from a solid position, combining both a historic presence in major industrial basins as well as a local anchoring thanks to Airgas. As part of the long-term contract signed with LG Chem, we will be putting our solutions at the service of the battery ecosystem in the United States. Additionally, through this investment, Airgas will more than double its local liquid nitrogen, oxygen and argon production which will enable us to support the increasing demand from merchant customers in Tennessee and surrounding states."
Airgas, Inc.
Airgas®, an Air Liquide company, is a leading U.S. supplier of industrial, medical and specialty gases, as well as hardgoods and related products; one of the largest U.S. suppliers of safety products; and a leading U.S. supplier of ammonia products and process chemicals.
Airgas helps its more than 1 million customers advance their business performance and reach their full potential with reliable products, services and expertise used to create, build, care, serve and sustain. With nearly 18,000 associates, over 1,400 locations, a robust eBusiness platform, and Airgas Total Access® telesales channel, Airgas is ready to help customers fill their potential, every day.
As an Air Liquide company, a world leader in gases, technology and services for Industry and Health, Airgas offers customers an unrivaled global footprint and industry-leading technology and innovations.
Air Liquide is a world leader in gases, technologies and services for industry and healthcare. Present in 60 countries with 66,300 employees, the Group serves more than 4 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the Group's activities since its creation in 1902.
Taking action today while preparing the future is at the heart of Air Liquide's strategy. With ADVANCE, its strategic plan for 2025, Air Liquide is targeting a global performance, combining financial and extra-financial dimensions. Positioned on new markets, the Group benefits from major assets such as its business model combining resilience and strength, its ability to innovate and its technological expertise. The Group develops solutions contributing to climate and the energy transition—particularly with hydrogen—and takes action to progress in areas of healthcare, digital and high technologies.
Air Liquide's revenue amounted to more than 27.5 billion euros in 2023. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, CAC 40 ESG, EURO STOXX 50, FTSE4Good and DJSI Europe indexes.
1Source: IEA
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015707866/en/
Contacts
Corporate Communications media@airliquide.com
Airgas Communications mediasupport@airgas.com
Investor Relations IRTeam@airliquide.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
European Penny Stocks Under €200M Market Cap To Watch
As the European markets experience a boost with the pan-European STOXX Europe 600 Index rising 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are looking for opportunities beyond traditional investments. Penny stocks, often representing smaller or newer companies, continue to capture attention due to their potential for significant returns when backed by strong financials. While the term 'penny stock' might seem outdated, these investments remain relevant today as they offer unique opportunities for those seeking hidden value in quality companies. Name Share Price Market Cap Financial Health Rating KebNi (OM:KEBNI B) SEK1.86 SEK504.35M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.72 SEK278.94M ★★★★★★ Cellularline (BIT:CELL) €3.16 €66.65M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.61 €17.24M ★★★★★★ Abak (WSE:ABK) PLN4.20 PLN11.32M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK2.40 SEK2.3B ★★★★☆☆ Hifab Group (OM:HIFA B) SEK3.64 SEK221.45M ★★★★★★ Euroland Société anonyme (ENXTPA:MLERO) €3.26 €9.49M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.185 €301.67M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.982 €32.88M ★★★★★★ Click here to see the full list of 444 stocks from our European Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases globally, with a market cap of €694.19 million. Operations: The company generates revenue primarily from its Recombinant Human C1 Esterase Inhibitor Business, amounting to $320.71 million. Market Cap: €694.19M Pharming Group, a biopharmaceutical company with a market cap of €694.19 million, has shown significant revenue growth, reporting US$79.09 million in Q1 2025 sales compared to US$55.59 million the previous year. Despite being unprofitable with a net loss of US$14.72 million for the quarter, it maintains over three years of cash runway and positive free cash flow. The company's debt-to-equity ratio has improved significantly from 104.9% to 41.1% over five years, and its short-term assets exceed liabilities by a substantial margin, indicating strong financial management amid high share price volatility and executive board changes. Jump into the full analysis health report here for a deeper understanding of Pharming Group. Gain insights into Pharming Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Arbona AB (publ) is an investment company focusing on small and medium-sized listed and unlisted companies in Sweden, with a market capitalization of approximately SEK1.70 billion. Operations: Arbona's revenue is primarily derived from three segments: Industry (SEK505.74 million), Transportation Technology (SEK120.59 million), and Properties (SEK9.88 million). Market Cap: SEK1.7B Arbona AB, with a market cap of SEK1.70 billion, focuses on investments in small and medium-sized companies. Despite trading at 36.8% below estimated fair value, its recent performance shows challenges such as negative earnings growth over the past year and lower profit margins compared to last year. However, Arbona's financial stability is underscored by satisfactory net debt to equity ratio (0.2%) and adequate coverage of short-term liabilities by assets (SEK412.4 million vs SEK171 million). The company's earnings have grown significantly over five years but were impacted by a large one-off gain of SEK162.3 million recently. Take a closer look at Arbona's potential here in our financial health report. Examine Arbona's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Ekobox S.A. is an engineering company based in Poland with a market capitalization of PLN70.17 million. Operations: The company's revenue is derived entirely from the Heavy Construction segment, amounting to PLN43.40 million. Market Cap: PLN70.17M Ekobox S.A., with a market cap of PLN70.17 million, operates in the Heavy Construction sector and recently reported a decline in quarterly revenue to PLN6.05 million from PLN10.28 million year-on-year, resulting in a net loss of PLN0.35 million. Despite challenges like high share price volatility and low return on equity (14.3%), Ekobox maintains financial stability with short-term assets exceeding both its short-term (PLN4.8M) and long-term liabilities (PLN2.4M). The company's debt levels have decreased significantly over five years, supported by robust operating cash flow coverage of its debt at 738.4%. Get an in-depth perspective on Ekobox's performance by reading our balance sheet health report here. Assess Ekobox's previous results with our detailed historical performance reports. Dive into all 444 of the European Penny Stocks we have identified here. Ready To Venture Into Other Investment Styles? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTAM:PHARM NGM:ARBO A and WSE:EBX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
28 minutes ago
- Business Insider
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ('Onconetix' or the 'Company'), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the 'Special Meeting') held on May 30, 2025, and that its Board of Directors (the 'Board of Directors' or 'Board') approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 13, 2025. Results of the Special Meeting At the Special Meeting, Onconetix's stockholders approved the following proposals: an amendment to the Onconetix, Inc. Amended and Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-10 to 1-for-150, at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be determined by the Board without further approval or authorization of the stockholders; and the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. (the 'Adjournment Proposal'). Final voting results from the Special Meeting were reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'SEC') on June 5, 2025. In conjunction with stockholder approval of the reverse stock split, the Company's Board of Directors determined to fix a split ratio of 1-for-85 shares. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on June 13, 2025. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'ONCO' under the new CUSIP number 68237Q203. The reverse stock split is intended to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market. At the effective time of the reverse split, every 85 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be canceled with the holders thereof receiving cash compensation. The amount of compensation will be determined by multiplying the fractional share by the closing price per share of the Company's common stock on The Nasdaq Capital Market at the close of business on the trading day prior to the effective date of the reserve stock split, or June 12, 2025. The reverse split will have no effect on the number of authorized shares of the Company's common stock, and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. The reverse stock split will additionally apply to the Company's common stock issuable upon exercise or conversion of the Company's equity awards, convertible preferred stock and warrants, as well as the applicable exercise price. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 44.4 million to approximately 521,863. About Onconetix, Inc. Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation. The Company also owns ENTADFI, an FDA-approved, once-daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia, a disorder of the prostate. For more information, visit Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements (including, without limitation, statements regarding the timing and effectiveness of the anticipated reverse split and compliance with applicable Nasdaq continued listing requirements) are based on Onconetix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; whether the Company will be able to regain and maintain compliance with Nasdaq's applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company's securities; whether a definitive agreement for the proposed transaction with Ocuvex Therapeutics, Inc. ('Ocuvex') and any related financing will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of a proposed transaction with Ocuvex; Onconetix's ability to integrate the assets and commercial operations contemplated to be acquired from Ocuvex into the Company's business; risks related to Onconetix's ability to commercialize or monetize Proclarix and integrate the assets and commercial operations; risks related to the Company's present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix's ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company's commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix's products; risks related to the Company's ability to obtain and maintain intellectual property protection for its current products; and the Company's reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix's Annual Report on Form 10-K, filed with the SEC on June 2, 2025 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. For more information: Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, OH 45202 Phone: (513) 620-4101
Yahoo
33 minutes ago
- Yahoo
Form 8.3 - Greencore, PLC
LONDON, June 13, 2025--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Polaris Capital Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Greencore Group plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 06/12/2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" No 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: ISIN: IE0003864109 Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 21,730,323 4.92 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 21,730,323 4.92 All interests and all short positions should be disclosed. *The change in the holding of 2,237,154 shares since the last disclosure dated 05/07/25 is due to a transfer out of shares in the discretionary holding. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit IE0003864109 SALE 159,231 2.3134 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None. (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? No Date of disclosure: 06/12/2025 Contact name: Elizabeth Murray Telephone number*: 617-951-0004 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit. The Code can be viewed on the Panel's website at View source version on Contacts Polaris Capital Management, LLC
